Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets

Overview

Journal PLoS Med

Specialty General Medicine

Date 2009 Apr 22

PMID 19381279

Citations 105

Authors

Surender Khurana

Amorsolo L Suguitan Jr

Yonaira Rivera

Cameron P Simmons

Antonio Lanzavecchia

Federica Sallusto

Jody Manischewitz

Lisa R King

Kanta Subbarao

Hana Golding

Affiliations

Soon will be listed here.

Abstract

Background: Transmission of highly pathogenic avian H5N1 viruses from poultry to humans have raised fears of an impending influenza pandemic. Concerted efforts are underway to prepare effective vaccines and therapies including polyclonal or monoclonal antibodies against H5N1. Current efforts are hampered by the paucity of information on protective immune responses against avian influenza. Characterizing the B cell responses in convalescent individuals could help in the design of future vaccines and therapeutics.

Methods And Findings: To address this need, we generated whole-genome-fragment phage display libraries (GFPDL) expressing fragments of 15-350 amino acids covering all the proteins of A/Vietnam/1203/2004 (H5N1). These GFPDL were used to analyze neutralizing human monoclonal antibodies and sera of five individuals who had recovered from H5N1 infection. This approach led to the mapping of two broadly neutralizing human monoclonal antibodies with conformation-dependent epitopes. In H5N1 convalescent sera, we have identified several potentially protective H5N1-specific human antibody epitopes in H5 HA[(-10)-223], neuraminidase catalytic site, and M2 ectodomain. In addition, for the first time to our knowledge in humans, we identified strong reactivity against PB1-F2, a putative virulence factor, following H5N1 infection. Importantly, novel epitopes were identified, which were recognized by H5N1-convalescent sera but did not react with sera from control individuals (H5N1 naïve, H1N1 or H3N2 seropositive).

Conclusion: This is the first study, to our knowledge, describing the complete antibody repertoire following H5N1 infection. Collectively, these data will contribute to rational vaccine design and new H5N1-specific serodiagnostic surveillance tools.

Citing Articles

Preparation and Antigenic Site Identification of Monoclonal Antibodies against PB1 Protein of H9N2 Subtype AIV.

Cai Y, Yin G, Hu J, Liu Y, Huang X, Gao Z Vet Sci. 2024; 11(9).

PMID: 39330791 PMC: 11435642. DOI: 10.3390/vetsci11090412.

Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design.

Khurana S, Grubbs G, Ravichandran S, Cluff E, Kim J, Kuehne A Nat Commun. 2024; 15(1):8133.

PMID: 39285186 PMC: 11405854. DOI: 10.1038/s41467-024-51021-5.

A broad-spectrum vaccine candidate against H5 viruses bearing different sub-clade 2.3.4.4 HA genes.

Zhang Y, Cui P, Shi J, Zeng X, Jiang Y, Chen Y NPJ Vaccines. 2024; 9(1):152.

PMID: 39160189 PMC: 11333769. DOI: 10.1038/s41541-024-00947-4.

Identification of specific neutralizing antibodies for highly pathogenic avian influenza H5 2.3.4.4b clades to facilitate vaccine design and therapeutics.

Duong B, Yeo S, Park H Emerg Microbes Infect. 2024; 13(1):2302106.

PMID: 38170506 PMC: 10810642. DOI: 10.1080/22221751.2024.2302106.

Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens.

Palma M Vaccines (Basel). 2023; 11(7).

PMID: 37514992 PMC: 10384025. DOI: 10.3390/vaccines11071176.

References

Simmons C, Bernasconi N, Suguitan A, Mills K, Ward J, Vinh Chau N . Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007; 4(5):e178. PMC: 1880850. DOI: 10.1371/journal.pmed.0040178. View

Wilson I, Skehel J, Wiley D . Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature. 1981; 289(5796):366-73. DOI: 10.1038/289366a0. View

Conenello G, Zamarin D, Perrone L, Tumpey T, Palese P . A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog. 2007; 3(10):1414-21. PMC: 2000966. DOI: 10.1371/journal.ppat.0030141. View

Smith C, Barnett B, Thomas D . Structural assignment of novel and immunodominant antigenic sites in the neutralizing antibody response of CBA/Ca mice to influenza hemagglutinin. J Exp Med. 1991; 173(4):953-9. PMC: 2190823. DOI: 10.1084/jem.173.4.953. View

Zamarin D, Ortigoza M, Palese P . Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. J Virol. 2006; 80(16):7976-83. PMC: 1563817. DOI: 10.1128/JVI.00415-06. View

Sandbulte M, Jimenez G, Boon A, Smith L, Treanor J, Webby R . Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 2007; 4(2):e59. PMC: 1796909. DOI: 10.1371/journal.pmed.0040059. View

Green N, Alexander H, Olson A, Alexander S, Shinnick T, Sutcliffe J . Immunogenic structure of the influenza virus hemagglutinin. Cell. 1982; 28(3):477-87. DOI: 10.1016/0092-8674(82)90202-1. View

Kaverin N, Rudneva I, Govorkova E, Timofeeva T, Shilov A, Kochergin-Nikitsky K . Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol. 2007; 81(23):12911-7. PMC: 2169086. DOI: 10.1128/JVI.01522-07. View

Rowe T, Abernathy R, Thompson W, Lu X, Lim W, Fukuda K . Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999; 37(4):937-43. PMC: 88628. DOI: 10.1128/JCM.37.4.937-943.1999. View

10.

Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou W, Fiers W . A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999; 5(10):1157-63. DOI: 10.1038/13484. View

11.

Stephenson I, Wood J, Nicholson K, Charlett A, Zambon M . Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 2004; 103(1-2):91-5. DOI: 10.1016/j.virusres.2004.02.019. View

12.

Fu T, Freed D, Horton M, Fan J, Citron M, Joyce J . Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology. 2008; 385(1):218-26. DOI: 10.1016/j.virol.2008.11.035. View

13.

Black R, Rota P, Gorodkova N, Klenk H, Kendal A . Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol. 1993; 74 ( Pt 1):143-6. DOI: 10.1099/0022-1317-74-1-143. View

14.

Gerhard W, Mozdzanowska K, Zharikova D . Prospects for universal influenza virus vaccine. Emerg Infect Dis. 2006; 12(4):569-74. PMC: 3294695. DOI: 10.3201/eid1204.051020. View

15.

Subbarao K, Joseph T . Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol. 2007; 7(4):267-78. PMC: 7097526. DOI: 10.1038/nri2054. View

16.

Throsby M, van den Brink E, Jongeneelen M, Poon L, Alard P, Cornelissen L . Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One. 2008; 3(12):e3942. PMC: 2596486. DOI: 10.1371/journal.pone.0003942. View

17.

de Jong M, Tran T, Truong H, Vo M, Smith G, Nguyen V . Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005; 353(25):2667-72. DOI: 10.1056/NEJMoa054512. View

18.

Stephenson I, Das R, Wood J, Katz J . Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine. 2007; 25(20):4056-63. DOI: 10.1016/j.vaccine.2007.02.039. View

19.

Wiley D, Wilson I, Skehel J . Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1981; 289(5796):373-8. DOI: 10.1038/289373a0. View

20.

Treanor J, Tierney E, Zebedee S, Lamb R, Murphy B . Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol. 1990; 64(3):1375-7. PMC: 249260. DOI: 10.1128/JVI.64.3.1375-1377.1990. View